Breast cancer incidence and mortality increase with age. A better understanding of the biological behavior of metastatic and nonmetastatic breast tumors in older subjects may help to develop improved breast cancer therapies. In this study, we used syngeneic metastatic (4TO7cg) and nonmetastatic (64pT) mouse breast tumor models at three age levels to evaluate Various characteristics that are considered to be important for effective anti-breast cancer immunotherapy. These included tomor size and growth, metastases, vascularization, gene expression levels of the tumor-associated antigen (TAA) Mage-b (homologous to human MAGE-B) in primary breast tumors and metastases, and the presence of CD4+ and CD8+ T cells in the inguinal lymph nodes at the site of the tumor. The primary breast tumors and metastases were generated by injection of mouse mammary tumor cell lines 4TO7cg or 64pT into a mammary fat Pad of normal 3-, 9-, or 21/24-month old BALB/c mice. In the nonmetastatic breast tumor model, significantly smaller tumors Were observed in old compared with young mice. This was associated with a significant increase in the percentage of CD8+ T cells in inguinal lymph nodes and significantly higher Mage-b expression levels in the primary tumors at old age. In the metastatic (4TO7cg) breast tumor model, a less pronounced, not statistically significant, smaller tumor size was found in the old mice, without a difference in the percentage of CD8+ T cells or Mage-b expression levels. However, in this mouse model almost all metastases showed high levels of Mage-b expression (2- to 3-fold higher than the primary tumors in the same animals) regardless of age. These results indicate that the metastatic and nonmetastatic breast tumor models could be useful model systems to analyze how breast cancer vaccines for humans can be tailored to old age.
ReichertJM, PaquetteC. Therapeutic cancer vaccines on trial. Nature Biotechnol20: 659–663, 2002.
2.
MussHB. Factors used to select adjuvant therapy of breast cancer in the United States: an overview of age, race, and socioeconomic status. J Natl Cancer Inst Monogr30: 52–55, 2001.
3.
KurtzJE, DufourP. Strategies for improving quality of life in older patients with metastatic breast cancer. Drugs Aging19: 605–622, 2002.
4.
ShahS, DoyleK, LangeEM, ShenP, PennellT, FerreeC, LevineEA, PerrierND. Breast cancer recurrence in elderly patients after lumpectomy. Am Surg68: 735–739, 2002.
5.
WiegelT, KreuselKM, BornfeldN, BottkeD, StangeM, FoersterM, HinkelbeinW. Frequency of asymptomatic choroidal metastasis in patients with disseminated breast cancer: results of a prospective screening study. Br J Opthalmol82: 1159–1161, 1998.
6.
AlberghAJ, SingS. Epidemiology of breast cancer in older women: implications for further health care. Drugs Aging18: 761–762, 2001.
7.
ErshlerWB. The aggressiveness of neoplasms with age. Geriatrics42: 99–103, 1984.
8.
TsudaT, KimYT, SiskindGW. Role of the thymus and T cells in slow growth of B16 melanoma in old mice. Cancer Res47: 3097–3102, 1987.
9.
RockwellS. Effect of host age on the transplantation, growth, and radiation response of EMT6 tumors. Cancer Res41: 527–531, 1981.
10.
ItzhakiO, SkutelskyE, KaptzanT, SiegalA, MichowitzM, SinaiJ, HuszarM, NafarS, LeiboviciJ. Macrophage-recognized molecules of apoptotic cells are expressed at higher levels in AKR lymphoma of aged as compared to young mice. Adv Exp Med Biol479: 251–262, 2000.
11.
MillerRA. The aging immune system: primer and prospectus. Science273: 70–74, 1996.
12.
MollsRR, AhluwaliaN, FickT, MastroAM, WagstaffD, HandteG, BallR. Inter- and intra-individual variation in tests of cell mediated immunity in young and old women. Mech Aging Dev124: 619–627, 2003.
13.
GeorgeAJT, RitterMA. Thymic involution with aging: obsolescence or good housekeeping?Immunol Today17: 267–272, 1996.
14.
PatriarciaPA. A randomized controlled trial of influenza vaccine in the elderly. Scientific scrutiny and ethical responsibility. JAMA272: 1700–1701, 1994.
15.
McElhaneyJE, MeneillyGS, LecheltKE, BleackleyRC. Split-virus influenza vaccines: do they provide adequate immunity in the elderly-Gerontology49: M37–M43, 1994.
16.
GravekampC, BontenbalM, RonteltapCPM, van DuivenbodeD, BolhuisRLH. In vitro and in vivo activation of CD4+ T lymphocytes by autologous tumor cells. Int J Cancer46: 152–154, 1990.
KoyamaS, MaruyamaT, AdachiS, NozueM. Expression of co-stimulatory molecules, B7-1 and B7-2 on human gastric carcinoma. J Cancer Res Clin Oncol124: 383–388, 1998.
19.
GarridoF, Ruiz-CabelloF, CabreraT, Perez-VillarJJ, Lopez-BotetM., Duggan-KeenM, SternPL. Implications for immunosurveillance of altered HLA class I phenotypes in human tumors. Immunol Today18: 89–95, 1997.
20.
AkbasakA, OldfieldEH, SarisSC. Expression and modulation of major histocompatibility antigens on murine brain tumors in vitro.Neurosurg75: 922–929, 1991.
21.
ParkJW, KwonTK, KimIH, SohnSS, KimCI, BaeOS, LeeKS, LeeKD, LeeCS, ChangHK, ChoeBK, AhnSY, JeonCH. A new strategy for the diagnosis of MAGE-expressing cancers. J Immunol79: 79–86. 2002.
22.
RosenbergSA, ZhaiY, YangJC, SchwartzentraberDJ, Hwu P-MarincolaFM, TopalianSL, RestifoNP, SeippCA, EinhornJH. Roberts B, White DE. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst90: 1984–1900, 1998.
23.
AnichiniA, MollaA, MortariniR, TragniG, BersaniI, NicolaMD, GianniM, DunbarR, CerundoloV, ParmianiG. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J Exp Med190: 651–668, 1999.
24.
MarchandM, van BarenN, WeynantsP, BrichardV, DrenoB, TessierMH, RankinE, ParmianiG, ArientiF, HumbletY, BourlondA, van WijckR, LienaardD, BeauduinM, BrasseurF, CouliePG, van der BruggenP, BoonT. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer80: 219–230, 1999.
25.
De BackerO, VerheydenAM, MartinB, GodelaineD, De PlaenE, BrasseurR, AvnerP, BoonT. Structure, chromosomal location, and expression pattern of three mouse genes homologous to the human MAGE genes. Genomics28: 74–83, 1995.
26.
De PlaenE, De BackerO, ArnaudD, BonjeanB, ChomezP, MartelangeV, AvnerP, BaldacciP, BabinetC, HwangSY, KnowlesB, BoonT. A new family of mouse genes homologous to the human MAGE genes. Genomics55: 176–184, 1999.
27.
SypniewskaRK, HoflackL, BearssDJ, GravekampC. Potential mouse tumor model for pre-clinical testing of Mage-specific breast cancer vaccines. Breast Cancer Res Treat74: 221–233, 2002.
28.
SypniewskaRK, HoflackL, TarangoM, GaunttS, ReddickRL, GravekampC. Prevention of metastases with a Mage-b DNA vaccine in a mouse breast tumor model: potential for breast cancer therapy. Breast Cancer Res Treat (submitted).
29.
GuayerbasN, De la FuenteM. An impairment of phagocytic function is linked to a shorter life span in two strains of premature mice. Dev Comp Immunol27: 339–350, 2003.
30.
RakJW, McEachernD, MillerFR. Sequential alteration of peanut agglutinin binding-glycoprotein expression during progression in murine mammary neoplasia. Br J Cancer65: 641–648, 1992.
31.
AslaksonCJ, McEachemD, ConawayDH, MillerFR. Inhibition of lung colonization at two different steps in the metastatic sequence. Clin Exp Metastasis9: 139–150, 1991.
32.
MillerFR, AslaksonCJ, McEachernD. Modulation of host resistance to metastasis in the lungs of aged retired breeder mice. Invasion Metastasis11: 233–240, 1991.
33.
ReevesJP, ReevesPA. Care and handling of laboratory animals. In: ColiganJE, KruisbeekAM, MarguliesDH, ShevachEM, StroberW, Eds. Current Protocols in Immunology. New York: Wiley, Vol 1:pp 1.9.1, 2003.
34.
GravekampC. Tailoring cancer vaccines to the elderly: the importance of suitable mouse tumor models. Mech Aging Dev122: 1087–1105, 2001.
35.
YancikR, RiesLG, YatesJW. Breast cancer in aging women. A population-based study of contrasts in stage, surgery, and survival. Cancer63: 976–981, 1989.
36.
BronsonRT. Rate of occurrence of lesions in 20 inbred and hybrid genotypes of rats and mice sacrificed at 6 month intervals during the first year of life. In: HarrisonDE, Ed. Genetics of Aging II. Caldwell, NJ: Telford Press, pp 280–358, 1990.
37.
ChenJ, FlurkeyK, HarrisonDE. A reduced peripheral blood CD4(+) lymphocyte proportion is a consistent aging phenotype. Mech Aging Dev123: 145–153, 2002.
38.
VijgJ. Somatic mutations and aging: a re-evaluation. Mutat Res447: 117–135, 2000.
39.
CampisiJ. Cancer and ageing: rival demons?Natl Rev Cancer. 3: 339–349, 2003.
40.
WascherRA, BostickPJ, HuynhKT, TurnerR, QiK, GiulianoAE, HoonDS. Detection of MAGE-A3 in breast cancer patients' sentinel lymph nodes. Br J Cancer85: 1340–1346, 2001.
41.
BrasseurF, RimoldiD, LienardD, LetheB, CarrelS, ArientiF, SuterL, VanwijckR, BourlondA, HumbletY. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer63: 375–380, 1995.
